The pharmacokinetics of chloroquine (CQ) and desethylchloroquine (DECQ) were studied in seven male Thai patients with P. vivax malaria and seven healthy male Thais, after the standard oral dosage regimen of CQ (a total dose of 1500 mg given over 3 days). All patients showed a rapid initial response to the treatment with median (range) values of fever and parasite clearance times of 13.7 (2-47) and 58 (33-38) h, respectively. In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-'), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) jg ml-' h ). In addition, the median (AUC(0,28d) of DECQ was significantly greater (170 (72-265) vs 77 (49-140) jg ml-1 h). The AUC(0,28d) ratio of DECQ to CQ in patients was significantly higher than that in healthy subjects (0.67 (0.43-0.90) vs 0.51 (0.29-0.61)).
Introduction
Chloroquine (CQ) is the treatment of choice for vivax malaria. However, in the past 5 years there have been increasing reports of recurrence of P. vivax parasitaemia after therapeutic or prophylactic regimens of CQ in some parts of the world [1] [2] [3] [4] [5] [6] [7] . In Thailand, in spite of the total loss of efficacy of chloroquine in the treatment of P. falciparum malaria, the efficacy of the drug against P. vivax malaria has been complete [8] [9] , although declining susceptibility of the parasite to CQ was observed in vitro (Tan-ariya et al., 1994, submitted for publication). The pharmacokinetics of CQ and its major plasma metabolite desethylchloroquine (DECQ) were compared in male Thai subjects with P. vivax malaria and healthy subjects, in order to define any differences which might account for altered response in patients.
Methods
Seven healthy male Thai subjects, and seven male Thai patients with P. vivax malaria, aged between 18 and 35 years and weighing 45 to 68 kg, were recruited for the study. Written informed consent for participation was obtained from each volunteer. The study was approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
The healthy subjects were non-smokers, non-drinkers and had no previous history of liver or kidney diseases. None was on regular medication and no other drugs were taken during the study. They were admitted to the Bangkok Hospital for Tropical Diseases on the first day of drug administration and returned for blood sampling daily until day 14, and again on days 21 F'1) . The flow rate was 2.8 ml min-' with u.v. detection at 254 nm. The limit of determination was S ng ml-' for CQ and 10 ng ml-' for DECQ. The intra-and inter-assay coefficients of variation were, respectively, 7.5% and 9.1% at 50 ng ml-', 5.9% and 1% at 500 ng ml-' and 7.8% and 6.1% at 1000 ng ml-' for CQ. The corresponding values for DECQ were 5.2% and 4.2% at 50 ng ml-, 2% and 1% at 500 ng ml-' and 9.2% and 1.4% at 1000 ng ml-'.
The maximum blood drug concentration (Cmax~) was defined as the highest concentration observed during the sampling time. An apparent elimination rate constant (X8-28d) was estimated by least squares regression anlaysis of at least 4 No subject had detectable levels of CQ and DECQ in their blood prior to treatment. Median plasma concentrations of CQ and DECQ in healthy subjects and patients are shown in Figure 1 , and median (range) pharmacokinetic parameters derived from the 0-28 day data are listed in Table 1 . The median (range) values of Cmax and AUC(0-28d) of CQ were significantly higher in the patients, as was the AUC(0-28d) of DECQ. The ratio of AUC values of DECQ to CQ in patients was significantly greater than that in healthy subjects (0.67 (0.43-0.90) vs 0.51 (0.29-0.61)).
Discussion
Blood concentrations of both CQ and DECQ observed in the study were similar to those reported by others [11] . After multiple oral doses of CQ in both malaria patients and healthy subjects, systemic exposure of CQ was always higher than that of DECQ. The higher Cmax and AUC values observed in the patients may reflect a change in the extent of absorption of the drug during the infection. The finding of no changes in the pharmacokinetics of CQ in patients infected with P. vivax after intravenous administration compared with healthy subjects [12] , and the high variability in the fraction of dose absorbed after oral administration noted in various studies [13, 14] support this possibility.
Despite these kinetic changes, no adverse reactions to CQ were seen. This should be advantageous as declining susceptibility of the parasite to the drug in vitro has been observed in Thailand (Tan-ariya et al., 1994, submitted for publication). Blood concentrations of CQ or DECQ associated with adequate treatment of P. vivax malaria have not been established rigorously, although plasma or serum concentrations of CQ of 15-30 ng ml-l or whole blood concentration of 90 ng ml-' have been suggested [15, 16] . Even though a prominent trend in declining susceptibility of P. vivax has been observed in vitro [17, Tan-ariya et al., 1994, submitted for publication), the results of a large clinical trial suggest that the drug is still very effective for the treatment of P. vivax malaria in Thailand (Karbwang et al., 1994 , submitted for publication). 
